Source facts
FDA issued an approval letter for JYLAMVO on 2026-05-29. The source metadata identifies NDA 212479 as a supplement. Review the exact FDA letter for the approved conditions and labeling.
US FDA source recordAL · Approval Letter
JYLAMVO — FDA Approval Letter (NDA 212479)
Issued to SHORLA. Application is approved as submitted.
Assyro regulatory brief
FreeWhat did FDA decide for JYLAMVO?
Source facts and Assyro context are separated so you can scan the action quickly without treating analysis as an FDA conclusion.
Key details in this letter
- 1FDA action: approval.
- 2Application: NDA 212479.
- 3Submission: supplement.
- 4Sponsor: SHORLA.
Suggested next step
Review the exact FDA letter for approved conditions, labeling, and postmarketing requirements.
Open the document workspaceFDA source document
Read the full FDA approval letter (PDF)
Loading document viewer…
Common questions about the JYLAMVO approval letter
Is JYLAMVO FDA approved?
This letter documents an FDA approval action: FDA approved NDA 212479 for JYLAMVO, sponsored by SHORLA, on May 29, 2026. Product may be marketed. Verify current status and labeling in the source letter, since later FDA actions can change them.
What is NDA 212479?
NDA 212479 is the application under which FDA issued this approval letter for JYLAMVO to SHORLA. The letter is dated May 29, 2026.
What happens after an FDA approval letter?
The sponsor may market the product in line with the approved labeling. Approval letters typically set post-approval obligations: submitting final content of labeling, meeting any postmarketing requirements or commitments listed in the letter, updating Orange Book patent information within 30 days for NDAs, and ongoing annual reporting under 21 CFR 314.81.